Loading...

Sara Alsterlind Hurvitz

Title(s)Associate Professor, Medicine
SchoolMedicine
Address760 Westwood Plaza 32-144
Los Angeles CA 90024
Phone(310) 829-5471
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With = 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020 Jul 17; JCO2000147. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A. PMID: 32678716.
      View in: PubMed   Mentions:    Fields:    
    2. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer. 2020 Jul; 8(2). Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS. PMID: 32718986.
      View in: PubMed   Mentions:    Fields:    
    3. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 May 29; JCO2000775. Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. PMID: 32468955.
      View in: PubMed   Mentions: 1     Fields:    
    4. Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Res Treat. 2020 Jun; 181(2):233-248. Drullinsky PR, Hurvitz SA. PMID: 32274666.
      View in: PubMed   Mentions:    Fields:    
    5. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 02 13; 382(7):610-621. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I. PMID: 31825192.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    6. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. PMID: 31825569.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    7. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel). 2019 Dec 10; 11(12). Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. PMID: 31835495.
      View in: PubMed   Mentions:
    8. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Target Oncol. 2019 12; 14(6):647-656. Kolberg HC, Colleoni M, Santi P, Demetriou GS, Segui-Palmer MA, Fujiwara Y, Hurvitz SA, Hanes V. PMID: 31620980.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 01; 26(5):1105-1113. Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. PMID: 31772121.
      View in: PubMed   Mentions:    Fields:    
    10. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2019 Nov 25. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. PMID: 31767793.
      View in: PubMed   Mentions: 2     Fields:    
    11. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2020 Mar; 25(3):e439-e450. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. PMID: 32162822.
      View in: PubMed   Mentions:    Fields:    
    12. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr. 2020 Feb; 4(1):pkz085. Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. PMID: 32337496.
      View in: PubMed   Mentions:
    13. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 Feb 01; 26(3):566-580. Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. PMID: 31615937.
      View in: PubMed   Mentions: 4     Fields:    
    14. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 Feb; 25(2):e214-e222. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. PMID: 32043771.
      View in: PubMed   Mentions: 1     Fields:    
    15. Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs. 2019 Jul; 79(11):1217-1230. McCann KE, Hurvitz SA, McAndrew N. PMID: 31254268.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Clinical features of pseudocirrhosis in metastatic breast cancer. Breast Cancer Res Treat. 2019 Sep; 177(2):409-417. Oliai C, Douek ML, Rhoane C, Bhutada A, Ge PS, Runyon BA, Wang X, Hurvitz SA. PMID: 31175499.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Is the duration of adjuvant trastuzumab debate still clinically relevant? Lancet. 2019 06 29; 393(10191):2565-2567. Hurvitz SA. PMID: 31178153.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 07 25; 381(4):307-316. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. PMID: 31166679.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    19. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 09 01; 37(25):2206-2216. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. PMID: 31157583.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    20. Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease. J Clin Oncol. 2019 05 01; 37(13):1044-1046. Hurvitz SA. PMID: 30875278.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Dose intensification of chemotherapy for early breast cancer in the age of de-escalation. Lancet. 2019 Apr 06; 393(10179):1390-1392. Hurvitz SA. PMID: 30739744.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clin Cancer Res. 2019 05 15; 25(10):2975-2987. Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. PMID: 30723140.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    23. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. PMID: 30593513.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. Cancer. 2019 02 15; 125(4):633-641. Bower JE, Asher A, Garet D, Petersen L, Ganz PA, Irwin MR, Cole SW, Hurvitz SA, Crespi CM. PMID: 30561795.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 05 01; 25(9):2717-2724. Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME. PMID: 30563931.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    26. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Ther Adv Med Oncol. 2018; 10:1758835918807339. Hurvitz S, Singh R, Adams B, Taguchi JA, Chan D, Dichmann RA, Castrellon A, Hu E, Berkowitz J, Mani A, DiCarlo B, Callahan R, Smalberg I, Wang X, Meglar I, Martinez D, Hobbs E, Slamon DJ. PMID: 30542377.
      View in: PubMed   Mentions:
    27. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer. 2018 11; 104:160-168. Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. PMID: 30359909.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    28. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol. 2018 10 01; 4(10):1367-1374. Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. PMID: 29862411.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    29. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J Clin Oncol. 2018 Sep 20; JCO2017748392. Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB. PMID: 30235087.
      View in: PubMed   Mentions: 4     Fields:    
    30. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur J Cancer. 2018 11; 103:147-154. Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. PMID: 30241001.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    31. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 08 23; 379(8):753-763. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. PMID: 30110579.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    32. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context. 2018; 7:212540. McCann KE, Hurvitz SA. PMID: 30116283.
      View in: PubMed   Mentions:
    33. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 2018 12; 36(6):1060-1071. Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J. PMID: 29980894.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    34. Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clin Cancer Res. 2018 11 01; 24(21):5206-5218. Bardia A, Hurvitz S. PMID: 29884743.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 07; 19(7):904-915. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. PMID: 29804902.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    36. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Mol Cancer Ther. 2018 05; 17(5):897-907. O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ. PMID: 29483214.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    37. Focal Irradiation and Systemic TGFß Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 06 01; 24(11):2493-2504. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH. PMID: 29476019.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    38. Harnessing the immune system in the battle against breast cancer. Drugs Context. 2018; 7:212520. Nakasone ES, Hurvitz SA, McCann KE. PMID: 29456568.
      View in: PubMed   Mentions:
    39. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 01; 19(1):115-126. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. PMID: 29175149.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    40. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clin Breast Cancer. 2018 04; 18(2):e205-e218. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 29050918.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic. J Oncol Pract. 2017 09; 13(9):e792-e799. Walling AM, D'Ambruoso SF, Malin JL, Hurvitz S, Zisser A, Coscarelli A, Clarke R, Hackbarth A, Pietras C, Watts F, Ferrell B, Skootsky S, Wenger NS. PMID: 28813191.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Res Treat. 2017 Nov; 166(1):145-156. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 28702891.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    43. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 07; 18(7):904-916. Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. PMID: 28576675.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCellsCTClinical Trials
    44. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. PMID: 28196257.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    45. Optimal Management of Early and Advanced HER2 Breast Cancer. Am Soc Clin Oncol Educ Book. 2017; 37:76-92. Hurvitz SA, Gelmon KA, Tolaney SM. PMID: 28561711.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. Oncotarget. 2016 Nov 29; 7(48):78577-78590. Huang Y, Burns DJ, Rich BE, MacNeil IA, Dandapat A, Soltani SM, Myhre S, Sullivan BF, Furcht LT, Lange CA, Hurvitz SA, Laing LG. PMID: 27713176.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    47. Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer. J Oncol Pract. 2016 11; 12(11):1039-1045. D'Ambruoso SF, Coscarelli A, Hurvitz S, Wenger N, Coniglio D, Donaldson D, Pietras C, Walling AM. PMID: 27577617.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic. Ann Surg Oncol. 2016 12; 23(Suppl 5):634-641. Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA. PMID: 27619940.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. Clin Adv Hematol Oncol. 2016 Jul; 14(7):520-30. Zhang B, Hurvitz S. PMID: 27379947.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016 06 03; 16:352. Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. PMID: 27259714.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    51. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 2016 06 20; 34(18):2115-24. André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. PMID: 27091708.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    52. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep. 2016 Feb 23; 14(7):1590-1601. Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR. PMID: 26876179.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    53. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol. 2016 Feb; 28(1):59-69. Hurvitz S, Mead M. PMID: 26694831.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    54. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016 Mar; 17(3):357-366. Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M. PMID: 26822398.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    55. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015 Dec; 16(16):1700-10. Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. PMID: 26596672.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    56. NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. Syst Rev. 2015 Oct 01; 4:133. Korner EJ, Morris A, Allen IE, Hurvitz S, Beattie MS, Kalesan B. PMID: 26428301.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. Breast cancer: The debate over post-mastectomy radiotherapy should continue. Nat Rev Clin Oncol. 2015 Oct; 12(10):567-8. Oliai C, Hurvitz SA. PMID: 26323387.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS. Endocr Pract. 2015 Sep; 21(9):1040-5. Villa NM, Li N, Yeh MW, Hurvitz SA, Dawson NA, Leung AM. PMID: 26121443.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015 Jul; 16(7):816-29. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. PMID: 26092818.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    60. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast. 2015 Jun; 24(3):182-90. Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ. PMID: 25747197.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    61. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb; 149(3):669-80. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. PMID: 25663547.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    62. Symptom burden and quality of life among women with HER2(+) metastatic breast cancer. Breast J. 2015 Mar-Apr; 21(2):208-10. Mayer M, Lang K, Hurvitz S, Lalla D, Federico V, Brammer M, Menzin J, Tripathy D. PMID: 25655357.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    63. Estrogen receptor (ER)a-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. J Biol Chem. 2015 Feb 27; 290(9):5566-81. Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL. PMID: 25468909.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    64. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med. 2014 Dec; 2(12):122. Wong DJ, Hurvitz SA. PMID: 25568875.
      View in: PubMed   Mentions:
    65. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med. 2014; 7:329-38. Sadeghi S, Olevsky O, Hurvitz SA. PMID: 25378946.
      View in: PubMed   Mentions:
    66. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014 Sep; 6(5):202-9. Peddi PF, Hurvitz SA. PMID: 25342987.
      View in: PubMed   Mentions:
    67. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014 Sep; 19(9):901-8. Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D. PMID: 25085897.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    68. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014 Aug; 1321:41-54. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. PMID: 25123209.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    69. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014 Jul 01; 20(13):3507-20. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ. PMID: 24879796.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    70. Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs. 2014 Jul; 23(7):1039-47. Hurvitz SA, Shatsky R, Harbeck N. PMID: 24870559.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    71. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res. 2014 May 23; 16(3):R50. Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, Gianni L. PMID: 24887458.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    72. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014; 3:259. Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD. PMID: 24926422.
      View in: PubMed   Mentions:
    73. Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. Springerplus. 2014; 3:244. Hurvitz SA, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, Slamon DJ. PMID: 24860718.
      View in: PubMed   Mentions:
    74. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014 May 02; 14:307. Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. PMID: 24885258.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    75. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer. Clin Adv Hematol Oncol. 2014 Apr; 12(4):260-2. Hurvitz S. PMID: 25003356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev. 2014 Jun; 40(5):614-25. Megerdichian C, Olimpiadi Y, Hurvitz SA. PMID: 24560997.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    77. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neurooncol. 2014 Mar; 117(1):7-13. Peddi PF, Hurvitz SA. PMID: 24469856.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    78. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 01; 120(5):642-51. Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D. PMID: 24222194.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    79. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res Treat. 2013 Dec; 142(3):603-9. Hurvitz SA, Lalla D, Crosby RD, Mathias SD. PMID: 24218050.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    80. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013 Oct; 141(3):437-46. Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, André F. PMID: 24101324.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    81. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev. 2014 Mar; 40(2):320-6. Peddi PF, Shatsky RA, Hurvitz SA. PMID: 24011786.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    82. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3693-702. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. PMID: 23658459.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    83. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013 Mar; 9(3):319-26. Peddi PF, Hurvitz SA. PMID: 23469968.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    84. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20; 31(9):1157-63. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. PMID: 23382472.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    85. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol. 2012 Sep; 4(5):235-45. Hurvitz SA, Kakkar R. PMID: 22942906.
      View in: PubMed   Mentions:
    86. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother. 2012 Sep; 35(7):534-43. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, Timmerman JM. PMID: 22892450.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    87. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2013 May; 39(3):219-29. Hurvitz SA, Hu Y, O'Brien N, Finn RS. PMID: 22658319.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    88. Analysis of Fc? receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15; 18(12):3478-86. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. PMID: 22504044.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    89. Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2012 Apr 03; 4:35-51. Hurvitz SA, Kakkar R. PMID: 24367193.
      View in: PubMed   Mentions:
    90. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. PMID: 21990397.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCTClinical Trials
    91. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2011 Apr; 12(4):369-76. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiello-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Baños A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR. PMID: 21429799.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    92. Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint. Cancer Treat Rev. 2011 Nov; 37(7):495-504. Hurvitz SA. PMID: 21315516.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    93. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011 Feb; 23(1):37-43. Callahan R, Hurvitz S. PMID: 21500375.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    94. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010 Dec 01; 28(34):5110-5. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. PMID: 20975068.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    95. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. PMID: 20705564.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    96. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009 Oct 15; 15(20):6446-53. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM. PMID: 19808874.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    97. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists. Oncologist. 2009 Sep; 14(9):883-90. Hurria A, Wong FL, Pal S, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A. PMID: 19726455.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    98. What's positive about 'triple-negative' breast cancer? Future Oncol. 2009 Sep; 5(7):1015-25. Hurvitz SA, Finn RS. PMID: 19792970.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    99. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 01; 113(9):2385-97. Hurvitz SA, Pietras RJ. PMID: 18819158.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    100. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol. 2008 Nov 20; 26(33):5386-92. Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A. PMID: 18955446.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    101. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008 Sep 15; 181(6):4131-40. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. PMID: 18768870.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    102. Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer. J Clin Oncol. 2008 Jan 10; 26(2):326-8. Ancheta RG, Lewin H, Said J, Hurvitz SA. PMID: 18182673.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol. 2005 Sep; 17(5):432-40. Hurvitz SA, Timmerman JM. PMID: 16093791.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    104. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005 Jun; 5(6):841-52. Hurvitz SA, Timmerman JM. PMID: 15952914.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    Sara's Networks
    Concepts (348)
    Derived automatically from this person's publications.
    _
    Co-Authors (27)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _